Wellspect HealthCare announces commitment to climate action with the Science Based Targets initiative (SBTi)
With its vision set on a net-zero value chain by 2045 and a significant reduction of emissions as early as 2030, Wellspect HealthCare (“Wellspect”), a subsidiary of Dentsply Sirona, Incorporated (“Dentsply Sirona”) is now announcing its commitment to the Science Based Targets initiative (“SBTi”). This commitment includes the setting of near- and long-term company-wide emission reductions in line with science-based net-zero with the SBTi. An independent verification and approval by the SBTi of Wellspect’s near and long-term targets is yet to follow.
“Sustainability is part of our overall business strategy. It is integrated across our value chain. Embedding globally recognized science-based targets in our sustainability management seems like the natural next step”, explains Svenn Poulsen, Group Vice President at Wellspect HealthCare.
Wellspect is overseeing a shift in its manufacturing processes whereby materials, machinery and energy sources are scrutinized and replaced with lower climate impact options. Earlier this year, Wellspect also announced the world’s first eco-labelled catheter.
To showcase its commitment to becoming a more sustainable business, Wellspect also discloses progress on realizing its ambitions annually.
“As an industry lead, it is our responsibility to reduce our carbon footprint and to drive a transition towards more responsible production across our industry. This is how we can make a real difference. For our customers as well society at large”, concludes Mr. Poulsen.
About the Science Based Targets initiative
The Science Based Targets initiative (SBTi) is a global body enabling businesses to set ambitious emissions reductions targets in line with the latest climate science. It is focused on accelerating companies across the world to halve emissions before 2030 and achieve net-zero emissions before 2050. The SBTi defines and promotes best practice in science-based target setting and independently assesses companies’ targets.
For additional information, please contact:
Maria Lundbäck, Head of Corporate Marketing Communication
maria.lundback@wellspect.com
Mobile: +46702811763
Wellspect Healthcare is a leading global provider of innovative medical devices that help people suffering from urinary retention or chronic constipation. More than 1 000 employees around the world are dedicated to making a difference to people who need our products and services. Wellspect is one of the worlds’ leading manufacturers of intermittent urinary catheters, with LoFric® as the most known brand. As a help to those with chronic or severe constipation Wellspect has developed what likely is the world’s most advanced irrigation system, Navina™, combining a high degree of user convenience, clinical effectiveness and connectivity into one smart system. Wellspect strives to become climate neutral and leave the smallest possible environmental footprint. The company, with headquarters in Mölndal, Sweden, is present in more than 30 countries, and part of Dentsply Sirona, the worlds´ largest manufacturer of professional dental technologies. The company’s shares are listed in the United States on NASDAQ under the symbol XRAY.
Tags:
